Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Targeted therapy based on target identification by genetic examinations is a promising
direction in the treatment of patients with a complicated course of inflammatory
myofibroblastic tumor. Recently, the main work covered in foreign publications, aimed at
finding additional methods of treatment, by identifying new targets for targeted therapy in
patients with unresectable IMT, but currently there is no standardized approach to the
treatment of IMT in children worldwide.
This study can show the benefits of the usage of crizotinib as targeted therapy in children
with ALK/ROS1 positive unresectable, progressive or reccurent inflammatory myofibroblastic
tumors. The main hypothesis is that crizotinib would increase an objective response rate in
this group of patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology